Resumen de acción TEVA
Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en TEVA a partir de nuestros controles de riesgos.
Competidores de Teva Pharmaceutical Industries Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.81 |
| 52 Week High | US$14.47 |
| 52 Week Low | US$7.09 |
| Beta | 1.06 |
| 1 Month Change | -2.13% |
| 3 Month Change | 17.73% |
| 1 Year Change | 56.22% |
| 3 Year Change | 27.75% |
| 5 Year Change | -7.25% |
| Change since IPO | 3,299.38% |
Noticias y actualizaciones recientes
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26
Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26Recent updates
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 203 Reasons To Buy Teva At $10
Apr 07Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?
Mar 24Teva Pharmaceutical: Prepare For Takeoff
Feb 16Rentabilidad de los accionistas
| TEVA | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 7.2% | -0.01% | 2.0% |
| 1Y | 56.2% | 9.5% | 22.3% |
Rentabilidad vs. Industria: TEVA superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 9.5% el año pasado.
Rentabilidad vs. Mercado: TEVA superó al mercado US, que obtuvo un rendimiento del 21.9% el año pasado.
Volatilidad de los precios
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: TEVA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TEVA (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1901 | 35,737 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited desarrolla, fabrica, comercializa y distribuye medicamentos genéricos, medicamentos especializados y productos biofarmacéuticos en Norteamérica, Europa, Israel y a escala internacional. Ofrece medicamentos genéricos en diversas formas farmacéuticas, como comprimidos, cápsulas, inyectables, inhalantes, líquidos, parches transdérmicos, pomadas y cremas; productos estériles, hormonas, medicamentos de alta potencia y sustancias citotóxicas en formas farmacéuticas parenterales y sólidas; y productos genéricos con dispositivos médicos y productos combinados. La empresa se centra en las áreas del sistema nervioso central (SNC), respiratorio y oncología.
Resumen de fundamentos de Teva Pharmaceutical Industries Limited
| Estadísticas fundamentales de TEVA | |
|---|---|
| Capitalización bursátil | US$15.64b |
| Beneficios(TTM) | -US$559.00m |
| Ingresos (TTM) | US$15.85b |
1.0x
Ratio precio-ventas (PS)-28.0x
Ratio precio-beneficio (PE)¿Está TEVA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TEVA | |
|---|---|
| Ingresos | US$15.85b |
| Coste de los ingresos | US$8.20b |
| Beneficio bruto | US$7.65b |
| Otros gastos | US$8.21b |
| Beneficios | -US$559.00m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 08, 2024
| Beneficios por acción (BPA) | -0.49 |
| Margen bruto | 48.25% |
| Margen de beneficio neto | -3.53% |
| Ratio deuda/patrimonio | 244.1% |
¿Cómo se ha desempeñado TEVA a largo plazo?
Ver rendimiento histórico y comparativa